Merck’s Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate) & Pifeltro (doravirine) Receives EU’s Approval for the Treatment of HIV-1 Infection

 Merck’s Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate) & Pifeltro (doravirine) Receives EU’s Approval for the Treatment of HIV-1 Infection

Merck’s Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate) & Pifeltro (doravirine) Receives EU’s Approval for the Treatment of HIV-1 Infection

Shots:

  • The approval is based on the results of P-III DRIVE-AHEAD and DRIVE-FORWARD trial assessing Delstrigo vs efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) & Pifeltro vs darunavir + ritonavir (DRV+r) + FTC/TDF or abacavir (ABC)/3TC respectively for a duration of 48/96 wks.
  • DRIVE-AHEAD and DRIVE-FORWARD results: suppression of HIV-1 RNA @ 48 wks. (84%, 83% vs 80%, 79%), suppression of HIV-1 RNA @ 96 wks. (76%, 72% vs 73%, 64%)
  • Delstrigo is qd fixed dose of doravirine (100 mg), lamivudine (3TC, 300 mg) and (TDF, 300 mg) & Pifeltro (doravirine, 100 mg) are non-nucleoside reverse transcriptase inhibitors (NNRTI) indicated for treatment of HIV-1 in adults

Click here to read full press release/ article | Ref: Merck | Image: Washington Times

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post